tert-butyl 2-(4,5-diamino-2-(4-fluorophenoxy)phenyl)pyrrolidine-1-carboxylate | 1186021-90-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 2-(4,5-diamino-2-(4-fluorophenoxy)phenyl)pyrrolidine-1-carboxylate
• CAS: 1186021-90-8
• 化学式: C₂₁H₂₆FN₃O₃
• 分子量: 387.454
• InChiKey: XFPQCYMLOZBOLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.85
• 重原子数：
  28.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  90.81
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  吡啶-2-甲醛 、 tert-butyl 2-(4,5-diamino-2-(4-fluorophenoxy)phenyl)pyrrolidine-1-carboxylate 以 乙醇 、 溶剂黄146 为溶剂， 以65%的产率得到tert-butyl 2-(5-(4-fluorophenoxy)-2-(pyridin-2-yl)-1H-benzo[d]imidazol-6-yl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators

  摘要：

  The synthesis and structure-activity-relationships (SARs) of novel 2-(pyridine-2-yl)-1H-benzimidazole glucokinase activators are described. Systematic modi. cation of benzimidazole lead 5a identified from a high-throughput screening led to the discovery of a potent and metabolically stable glucokinase activator 16p(R) with greater structural diversity from GKAs reported to date. The compound also demonstrated acute oral glucose lowering efficacy in rat OGTT model. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.05.038
• 作为产物：
  描述：

  tert-butyl 2-(4-amino-2-(4-fluorophenoxy)-5-nitrophenyl)pyrrolidine-1-carboxylate 在 肼 作用下， 以 甲醇 为溶剂， 以90%的产率得到tert-butyl 2-(4,5-diamino-2-(4-fluorophenoxy)phenyl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators

  摘要：

  The synthesis and structure-activity-relationships (SARs) of novel 2-(pyridine-2-yl)-1H-benzimidazole glucokinase activators are described. Systematic modi. cation of benzimidazole lead 5a identified from a high-throughput screening led to the discovery of a potent and metabolically stable glucokinase activator 16p(R) with greater structural diversity from GKAs reported to date. The compound also demonstrated acute oral glucose lowering efficacy in rat OGTT model. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.05.038